43 results
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. Viking’s
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
4 Mar 24
Other Events
4:52pm
in clinical trials. Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
, with three compounds currently in clinical trials. Viking’s research and development activities leverage its expertise in metabolism to develop innovative
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed
8-K
EX-99.1
sk90i8d3s c148aa5
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
ky345p6p40 s4gnz
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
8-K
EX-99.1
cpsswav7q
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
urgxwj3nvwxmnoe13gaf
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
EX-99.1
1vrgwe eb200pn
3 Apr 23
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters’ Option to Purchase Additional Shares
5:17pm
8-K
EX-99.1
rqfprz8y0gg2zuqy
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
8-K
EX-99.1
uyk6qzs0gqcjic
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
8-K
EX-99.1
cfm wt7le
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
4zpepkn jg8
27 Apr 22
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:44pm
8-K
EX-99.1
v6b0mqkgbc1untt8
9 Feb 22
Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
8stqlnu
3 Nov 21
Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
EX-99.1
uv9zzo 0dm9ylci
28 Jul 21
Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:12pm
8-K
EX-99.1
2oixeuhoxco7
28 Apr 21
Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:10pm